-
Lantern Pharma Shares Moves Higher On Encouraging Data From Pancreatic Cancer Candidate In Animal Models
Tuesday, July 20, 2021 - 8:12am | 227Read More...Lantern Pharma Inc (NASDAQ: LTRN) has announced new preclinical data from its ongoing pancreatic cancer collaboration with the Pancreatic Cancer Institute at Fox Chase Cancer Center. These data demonstrated that the drug candidate, LP-184, exhibited significant and rapid...
-
Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer
Tuesday, June 22, 2021 - 10:36am | 220Read More...Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer. The trial evaluated relacorilant plus nab-paclitaxel in pancreatic cancer patients who had relapsed following at least...
-
Oncolytics Pelareorep/Pembrolizumab Combo Therapy Shows Anti-Cancer Activity In Pancreatic Cancer
Thursday, May 20, 2021 - 1:57pm | 302Read More...Oncolytics Biotech Inc (NASDAQ: ONCY) has announced new data from Phase 2 trial evaluating pelareorep in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) in pancreatic cancer. Data will be presented at the 2021 American Society of Clinical...
-
AzurRx BioPharma Stock Gains On Positive MS1819-PERT Combo Data In Pancreatic Insufficiency
Thursday, May 13, 2021 - 8:49am | 298Read More...AzurRx BioPharma Inc (NASDAQ: AZRX) announced positive interim data from the first 18 out of 20 patients from its Phase 2 trial. The study was evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT),...
-
Galera Therapeutics Stock Surges After Its Lead Candidate Shows Median OS Of 20 Months In Pancreatic Cancer Study
Thursday, April 29, 2021 - 6:28am | 316Read More...Galera Therapeutics Inc (NASDAQ: GRTX) has announced updated results from its Phase 1/2 pilot trial evaluating GC4419 in patients with locally advanced pancreatic cancer (LAPC) who are undergoing stereotactic body radiation therapy (SBRT). The company plans to report final...
-
XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer
Monday, April 19, 2021 - 7:08am | 284Read More...The FDA has signed off Phase 1/2 clinical study to evaluate XBiotech Inc's (NASDAQ: XBIT) XB2001 when added to the ONIVYDE/5-FU combination therapy for treating patients with pancreatic cancer. The Phase 1 portion of the study will examine increasing doses of XBiotech...
-
Why Surface Oncology Shares Spiked 19% Today
Tuesday, March 30, 2021 - 11:49pm | 364Read More...Shares of Surface Oncology Inc. (NASDAQ: SURF), a clinical-stage biopharma company, gained more than 19% in the extended session on Tuesday. What Happened: The spike in shares came after the Cambridge, Massachusetts-based company said Tuesday that one of its lead therapeutic candidates, SRF617, has...
-
AIM ImmunoTech Gets Orphan Drug Tag For Ampligen In Pancreatic Cancer
Wednesday, February 24, 2021 - 2:57pm | 308Read More...AIM ImmunoTech Inc's (NYSE: AIM) subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission for Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer. Among other benefits, products with Orphan...
-
AIM ImmunoTech To Include New Patients In Netherlands Pancreatic Cancer Program
Wednesday, February 10, 2021 - 12:17pm | 327Read More...AIM ImmunoTech Inc (NYSE: AIM) shares are rising today after the company announced that the Netherlands regulatory authority had approved treatment for six pancreatic cancer patients as part of a new, follow-up Early Access Program (EAP). Subject to further authorization, the...
-
DSMB Recommends Hold On SBP-101 Administration In Early-Stage Metastatic Pancreatic Cancer Study, Shares Tank
Wednesday, February 10, 2021 - 9:50am | 290Read More...Independent data safety monitoring board (DSMB) has recommended a hold on Panbela Therapeutics Inc's (NASDAQ: PBLA) ongoing Phase 1 trial to hold the administration of SBP-101 pending further investigation of visual disturbance adverse events. The company...
-
NantKwest Reports Positive Interim Data In Pancreatic Cancer Trials, Stock Soars
Thursday, January 14, 2021 - 7:44am | 539Read More...Clinical-stage immunotherapy company Nantkwest Inc (NASDAQ: NK) reports positive interim data on survival rates in the Metastatic Pancreatic Cancer QUILT 88 trial on Wednesday. What Happened: Nantkwest said that early interim results of its PD-L1 t-haNK protocols showing...
-
Merrimack Plummets 30% After Pancreatic Cancer Drug Doesn't Meet Endpoints
Monday, June 25, 2018 - 10:29am | 320Read More...Merrimack Pharmaceuticals Inc (NASDAQ: MACK) plunged more than 30 percent Monday after management discontinued the development of MM-141. The drug’s Phase 2 trial for MM-141 in front-line metastatic pancreatic cancer did not meet primary or secondary endpoints. Why It’s Important...
-
EXCLUSIVE: VolitionRX CEO Talks Trial Updates, Time Until Market
Wednesday, January 6, 2016 - 10:00am | 418Read More...VolitionRX Ltd (NYSE: VNRX) stirred up some interest in the biotech community with blood tests that can predict colon cancer. What this means is that patients may no longer have to subject themselves to an invasive colonoscopy. In an exclusive interview with Benzinga, CEO Cameron Reynolds...
-
New Drug Could Transform Pancreatic Cancer Treatment
Monday, May 18, 2015 - 2:16pm | 336Read More...Halozyme Therapeutics, Inc. (NASDAQ: HALO) has developed a new drug called PEGPH 20, which is changing the way pancreatic cancer patients are treated. Helen Torley, Halozyme Therapeutics CEO, was on CNBC Monday to shed more light on the drug and the success it has had. PEGPH 20 "Some...
-
13 Drug Companies Trying to Beat the Odds in Pancreatic Cancer
Monday, October 24, 2011 - 12:00pm | 3975Read More...By MD Becker Partners November marks Pancreatic Cancer Awareness Month. According to the American Cancer Society, more than 44,000 new cases of pancreatic cancer will be diagnosed in the U.S. and over 37,000 deaths are expected from the disease in 2011. It has the highest mortality rate...
